Trials / Completed
CompletedNCT05821387
Evaluating the Safety, Tolerability, Pharmacokinetics, and Effect of Food of Lucid-21-302 in Healthy Volunteers
A Randomized, Double-Blind, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Lucid-21-302 in Healthy Volunteers Under Fed and Fasted Conditions
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Quantum Biopharma · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
This study aims to determine the safety, tolerability, and pharmacokinetics of single doses of Lucid-21-302 in healthy adult volunteers. This study will also investigate the effects of food in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lucid-21-302 | A small molecule inhibitor of hypercitrullination |
| DRUG | Placebo | Product containing excipients with no active ingredients |
Timeline
- Start date
- 2023-03-22
- Primary completion
- 2023-07-29
- Completion
- 2023-07-29
- First posted
- 2023-04-20
- Last updated
- 2023-08-29
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT05821387. Inclusion in this directory is not an endorsement.